Autoimmune diseases, their pharmacological treatment and the cardiovascular system

Cardiology Journal

Volumn 20, Issue 6, 2013, Pages 569-576

  Jastrzebska, Marta ^a   Czok, Michael E ^b   Guzik, Przemysław ^a,b  

^a Ginekologiczno Po o niczy Szpital Kliniczny im Heliodora wi cickiego Uniwersytetu Medycznego im Karola Marcinkowskiego   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adverse drug effects; Autoimmune diseases; Cardiovascular complications; Heart failure

Indexed keywords

CHLOROQUINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FLURBIPROFEN; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PIROXICAM; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ACUTE CORONARY SYNDROME; ANTIPHOSPHOLIPID SYNDROME; ASTHMA; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EDEMA; EMBOLISM; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; INFLAMMATION; KIDNEY FAILURE; LUNG FIBROSIS; MYOCARDITIS; PERICARDIAL EFFUSION; PERICARDITIS; POLYMYOSITIS; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THROMBOEMBOLISM; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CARDIOVASCULAR DISEASES; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84890343225     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2013.0156     Document Type: Review

References (71)

1. Bonow RO, Mann DL, Zipes DP et al. Braunwald's heart disease: A textbook of cardiovascular medicine. Saunders, Philadelphia 2011: 2107-2116.
2. Knockaert DC. Cardiac involvement in systemic inflammatory diseases. Eur Heart J, 2007; 28: 1797-1804.
3. Villa-Forte A, Mandell BF. Cardiovascular disorders and rheumatic disease. Rev Esp Cardiol, 2011; 64: 809-817.
4. Kitas G, Banks MJ, Bacon PB. Cardiac involvement in rheumatoid disease. Clin Med, 2001; 1: 18-21.
5. Crozier IG, Li E, Milne MJ, Nicholls MG. Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol, 1990; 65: 1145-1148.
6. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus, 2005; 14: 683-686.
7. Rosenbaum E, Krebs E, Cohen M et al. The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus, 2009; 18: 608-612.
8. Nihoyannopoulos P, Gomez PM, Joshi J et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation, 1990; 82: 369-375.
9. Fernández-Dueñas J, López-Granados A. Severe mitral regurgitation in libman-sacks endocarditis conservative surgery. Rev Esp Cardiol, 2005; 58: 1118-1120.
10. Moaref AR, Afifi S, Rezajan S, Rezajan GR. Isolated tricuspid valve libman-sacks endocarditis and valvular stenosis: Unusual manifestations of systemic lupus erythematosus. J Am Society Echocardiog, 2010; 23: 341-345.
11. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc, 1999; 74: 275-284.
12. Moyssakis I, Tekonidou M, Vassilios V et al. Libman-Sacks endocarditis in systemic lupus erythematosus: Prevalence, associations, and evolution. Am J Med, 2007; 120: 636-642.
13. Van der Laan-Baalbergen NE, Mollema SA, Kritikos H. Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus. Neth J Med, 2009; 67: 295-301.
14. Ohara N, Myiata T, Kurata A, Oshiro H, Sato O, Shigematsu H. Ten years' experience of aortic aneurysm associated with systemic lupus erythematosus. Eur J Vasc Endovasc Surg, 2000; 19: 288-293.
15. Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med, 1996; 335: 1424-1430.
16. Johnson SR, Gladman DD, Urowitz MB, Ibanez D, Granton JT. Pulmonary hypertension in systemic lupus erythematosus. Lupus, 2004; 13: 506-509.
17. Jordan JM, Valenstein P, Kredich DW. Systemic lupus erythematosus with Libman-Sachs Endocarditis in a 9-month-old infant with neonatal lupus erythematosus and congenital heart block, Pediatrics,1989; 84: 574-578.
18. Urowitz MB, Gladman D, Ibanez D. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus, arthritis. Care Res, 2010; 62: 881-887.
19. Asherson RA, Cervera R. Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation, 1991; 84: 920-923.
20. Bili A, Moss AF, Francis CW et al. Anticardiolipin antibodies and reccurent coronary events: a prospective study of 1150 patients. Circulation, 2000; 102: 1258-1263.
21. Greco T, Conti-Kelly AM, Doyle R et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol, 2009; 132: 613-620.
22. Gurlek A, Ozdol C, Pamir G et al. Association between anticardiolipin antibodies and recurrent cardiac events in patients with acute coronary syndrome. Int Heart J, 2005; 46: 631-638.
23. Vaarala O, Mänttäri M, Manninen V et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation, 1995; 91: 23-27.
24. Koniari I, Siminelaki SN, Baikoussis GN et al. Antiphospholipid syndrome; its implication in cardiovascular diseases: A review. J Cardiothorac Surg, 2010; 5: 101.
25. Turiel M, Muzzupappa S, Gottardi B. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus, 2000;9:406-412.
26. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation, 1996;92:1579-1587.
27. Plastiras SC, Toumanidis ST. Systemic sclerosis: The heart of the matter, hellenic. J Cardiol 2012; 53: 287-300.
28. Byers RJ, Marshall DAS, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis, 1997; 56: 393-394.
29. Nakajima K, Kawano M, Hasegawa M et al. Myocardial damages in systemic sclerosis detected by gated myocardial perfusion SPECT sympathetic imaging. Circ J, 2006; 70: 1481-1487.
30. Vacca A, Siotto P, Cauli A et al. Absence of epicardial coronary stenosis in patients with systemic sclerosis and severe impairment of coronary flow reserve. Ann Rheum Dis, 2006; 65: 274-275.
31. York M, Farber HW. Pulmonary hypertension: Screening and evaluation in scleroderma. Curr Opin Rheumatol, 2011; 23: 536-544.
32. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mildmoderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol, 2006; 33: 269.
33. Mathai SC, Hummers LK, Champion H. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases impact of interstitial lung disease. Arthritis Rheum, 2009; 60: 569-577.
34. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. Rheumatolog, 2009; 48: 45-48.
35. Moyssakis I, Gialafos E, Vassiliou V et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology, 2005; 44: 251-254.
36. Nomeir AM, Turner RA, Watts LE. Cardiac involvement in rheumatoid arthritis: follow-up study. Arthritis Rheum, 1979; 22: 561-564.
37. Nicola P, Crowson CS, Maradit-Kremers H et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum, 2006; 54: 60-67.
38. Udayakumar N, Venkatesan S, Rajendiran C. Diastolic function abnormalities in rheumatoid arthritis: relation with duration of disease. Singapore Med J, 2007; 48: 537.
39. Chung CP, Oeser A, Raggi P et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis. Arthritis Rheum, 2005; 52: 3045-3053.
40. Francis ML, Varghese JJ, Mathew JM et al. Outcomes in patients with rheumatoid arthritis and myocardial infarction. Am J Med, 2010; 123: 922-928.
41. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine, 2003; 82: 407-413.
42. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med, 2008; 121: 53-58.
43. Maradit-Kremers H, Crowson CS, Nicola P. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis a population-based cohort study. Arthritis Rheum, 2005; 52: 402-411.
44. Seyfeli E, Guler H, Akoglu S et al. Right ventricular diastolic abnormalities in rheumatoid arthritis and its relationship with left ventricular and pulmonary involvement. Int J Cardiovasc Imag, 2006; 22: 745-754.
45. Roldan CA, DeLong C, Qualls C, Crawford MH. Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echocardiography and clinical correlates. Am J Cardiol, 2007; 100: 496-502.
46. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet, 2002; 359: 1173-1177.
47. Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology, 2006; 45: 4-7.
48. Kremers HM, Crowson CS, Therneau TM et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study. Arthritis Rheumatism, 2008; 58: 2268-2274.
49. Lundbegr IE. The heart in dermatomyositis and polymyositis. Rheumatology, 2006; 45: 18-21.
50. Linos E, Fiorentino D, Lingala B. Atherosclerotic cardiovascular disease and ermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Therapy, 2013; 15: 1-5.
51. Bergfeldt L. HLAB27-associated cardiac disease. Ann Intern Med, 1997; 127: 621-629.
52. Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease associated with ankylosing spondylitis. Am Coll Cardiol, 1998; 32: 1397-1404.
53. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: Do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol, 2006; 25: 24-29.
54. Fardet L. Corticosteroid-induced clinical adverse events: Frequency, risk factors and patient's opinion. Br J Dermato, 2007; 157: 142-148.
55. Nakajima A, Doki K, Homma M et al. Investigation of glucocorticoidinduced side effects in patients with autoimmune diseases. Yakugaku Zasshi, 2009; 129: 445-450.
56. Naranjo A, Sokka T, Dezcalzo MA et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther, 2008; 10: 1-10.
57. Tisseverasinghe A, Bernatsky S, Pineau C. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol, 2009; 36: 1-4.
58. Batlouni M. Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects. Arq Bras Cardiol, 2010; 94: 556--563.
59. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med, 2009; 169: 141-149.
60. Zhao SZ, Burke T. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care, 2002; 8: 414-427.
61. Costedoat-Chalumeau N, Hulot JS. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology, 2007; 46: 808-810.
62. Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs, 2002; 62: 1599-1609.
63. Guedira N, Hajjaj-Hassouni N, Srairi JE et al. Third-degree atrioventricular block in a patient under chloroquine therapy. Rev Rhum Engl Ed, 1998; 65: 58-62.
64. Veinot JP, Mai KT, Zarychanski R. Chloroquine related cardiac toxicity. J Rheumatol, 1998; 25: 1221-1225.
65. Costedoat-Chalumeau N, Hulot JS, Amoura Z. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology, 2007; 107: 73-80.
66. Fragasso G, Sanvito F, Baratto F. Cardiotoxicity after low-dose chloroquine antimalarial therapy. Heart Vess, 2009; 24: 385-387.
67. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis, 2009; 68: 1100-1104.
68. Curtis JR, Kramer J, Martin M et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-a antagonists. Rheumatology, 2007; 46: 1688-1693.
69. Piot Ch, Croisille P, Staat P. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med, 2008; 359: 473-481.
70. Mewton N, Croisille P, Gahide G et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol, 2010; 55: 1200-1205.
71. Grizzard JD, Biondi-Zoccai G. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial). Am J Cardiol, 2010; 105: 1371-1377.